骨关节炎的经济和人文负担:大型样本研究的更新系统审查
Xuejing Jin1, Wanxian Liang1, Lining Zhang1
1Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No. 11, Bei San Huan Dong Lu, Chaoyang District, Beijing, China.
PharmacoEconomics
|July 18, 2023
概括
骨关节炎 (OA) 继续给全球患者带来重大的经济和人文负担. 自2016年以来,与OA相关的直接成本已经扩大,患者与健康相关的生活质量 (HRQL) 仍然很差.
科学领域:
- 类风湿病学 类风湿病学
- 卫生经济学 卫生经济学
- 公共卫生 公共卫生
背景情况:
- 骨关节炎 (OA) 带来了巨大的经济和人文负担.
- 之前的审查强调了OA对患者的重大影响.
- 需要进行更新的审查,以反映最近有关OA负担的数据.
研究的目的:
- 系统审查和更新骨关节炎 (OA) 的经济和人文负担.
- 分析自2016年以来发表的大型样本研究的数据.
- 提供当前的洞察力,了解OA的多方面的负担.
主要方法:
- 在Medline和Embase的系统文献搜索.
- 包括样本大小≥1000的研究,测量OA成本或与健康有关的生活质量 (HRQL).
- 两名研究人员与仲裁员进行独立审查,以查找差异;成本转换为2021美元.
主要成果:
- 包括54项研究,具有很高的审稿人一致性 (Kappa=0.71).
- 每年直接的OA成本在326美元 (日本) 到19,530美元 (美国) 之间;间接成本在736美元 (美国) 到18884美元 (荷兰) 之间.
- 与健康相关的生活质量 (HRQL) 仍然很差,EQ-5D和WOMAC是常见的衡量标准.
结论:
- 自2016年以来,OA的经济负担显示出更广泛的成本范围.
- 与OA相关的患者健康相关生活质量 (HRQL) 仍然很差.
- 需要注意的是,国际注册数据库中的OA负担数据越来越多地公布.
相关概念视频
Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
Osteoclasts in Bone Remodeling
3.0K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.0K
Atherosclerosis III: Management
13
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
13


